Ingenuity Signs $6M CRADA with FDA to Develop Biomarker, PGx Informatics | GenomeWeb
NEW YORK (GenomeWeb News) - Ingenuity Systems has entered into a three-year, $6 million Cooperative Research and Development Agreement with the US Food and Drug Administration that will expand the company’s content and software used in biomarker, Pharmacogenomic, and toxicogenomic research, the company said today.
Ingenuity said the partnership is aimed at supporting the FDA’s drug toxicity and side-effects research programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.